百濟神州(06160.HK)與生科公司Shoreline達全球獨家戰略合作
百濟神州(06160.HK)公布,與Shoreline Biosciences達成全球獨家戰略合作,聯動Shoreline的iPSC NK細胞技術與百濟神州的臨床前研發和臨床開發能力,開發並商業化一系列基於NK細胞療法的產品組合,用於治療各類惡性腫瘤。
Shoreline是一家生物科技公司,致力於運用智慧技術,通過誘導多能幹細胞(iPSC),設計開發同種異體即用型、標準化靶向自然殺傷(NK)細胞和巨噬細胞療法,用於治療癌症和其他嚴重疾病。
根據協議條款,Shoreline將從百濟神州處獲得4,500萬美元的現金預付款,並有資格在達到特定研發、註冊、商業化里程碑時獲得研發資金、里程碑付款和特許權使用費。雙方已就此項多靶點合作達成共識,將共同合作,針對4個治療靶點中開發細胞療法,並有權在未來擴大合作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.